@article{ETD,
      school = {Ph.D.},
      author = {Broeckel, Rebecca},
      url = {http://digitalcollections.ohsu.edu/record/7616},
      title = {Discovering new vaccines and therapeutics to treat  chikungunya virus infections: characterization of an  antiviral, a therapy, and a vaccine},
      publisher = {Oregon Health and Science University},
      abstract = {Chikungunya virus (CHIKV) is a mosquito-borne alphavirus  that causes acute febrile illness and long-lasting joint  and muscle pain. The 2013-2016 CHIKV outbreaks in the  Americas is one example of how CHIKV can rapidly spread  through areas of CHIKV seronegative individuals and cause  widespread severe and debilitating arthritic disease. Since  there is no currently available licensed vaccine or  antiviral for preventing or treating CHIKV and other  alphaviruses, there is urgent need to understand the basic  processes of viral replication and viral immunity to  develop effective prophylactic and therapeutic treatments.  In my dissertation, I describe three different strategies  to uncover new aspects of CHIKV biology by testing a small  molecule inhibitor, a monoclonal antibody therapy, and a  novel T cell vaccine.},
      number = {ETD},
      doi = {https://doi.org/10.6083/m4bc3z3s},
      recid = {7616},
      address = {2017},
}